A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SLV337 in Patients With Type 2 Diabetes on Metformin Monotherapy.
Phase of Trial: Phase II
Latest Information Update: 01 Feb 2016
At a glance
- Drugs SLV 337 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 03 Dec 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Nov 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.